Product Code: SR1523A313_Report
The global catheter-directed thrombolysis devices market size reached US$ 356.7 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 489.0 Million by 2028, exhibiting a growth rate (CAGR) of 5.5% during 2023-2028.
Thrombolysis refers to a minimal-invasive endovascular therapy that is adopted for treating clots in blot vessels and regulating the blood flow to prevent any damage in tissues and organs. It generally involves injecting clot-busting drugs via an intravenous (IV) line or through catheter-directed thrombolysis (CDT) device, which delivers the drugs directly to the blocking sites for anticoagulation. Catheter-directed thrombolysis devices mostly include a catheter, x-ray tubes, specific medications, and medical equipment to dissolve the blood clots. Apart from this, they also consist of a radiographic table and a monitor that helps in visualizing the anticoagulation process. CDT devices are safer than conventional surgical techniques, such as surgical balloon thrombectomy, thereby limiting hospital stay durations while lowering the chances of patient trauma and complications.
Catheter-Directed Thrombolysis Devices Market Trends:
- The growing prevalence of numerous chronic diseases, such as cancer, obesity, coronary heart disorders, kidney ailments, etc., is one of the primary factors driving the global catheter-directed thrombolysis devices market. In line with this, the rising consumer health awareness towards early detection and treatment of pulmonary embolism and deep vein thrombosis diseases, is also propelling the market growth. Additionally, the expanding geriatric population, who are more prone to serious medical conditions, is further augmenting the need for minimal-invasive therapies, involving CDT devices. Besides this, increasing investments by numerous government bodies in the healthcare sector, along with the rising consumer medical expenditures, are also bolstering the global market. Moreover, continuous advancements in CDT devices for mitigating the risk of post-thrombotic syndrome (PTS) and providing high-quality patient care are further catalyzing the market growth. Several healthcare professionals are getting inclined towards MI surgeries as a safer alternative than conventional open surgeries, which is acting as another growth-inducing factor. In the coming years, the emergence of pharmacomechanical CDT (PCDT) techniques for reducing treatment time and associated healthcare costs, is expected to drive the growth of the global CDT devices market.
Key Market Segmentation:
- IMARC Group provides an analysis of the key trends in each sub-segment of the global catheter-directed thrombolysis devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on delivery mode, indication and end user.
Breakup by Delivery Mode:
- Directly Delivery to Blood Clot
- Positioning Medical Device at Clot Site
Breakup by Indication:
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Stroke
- Others
Breakup by End User:
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
- The report has also analysed the competitive landscape of the market with some of the key players being AngioDynamics, Inc., Boston Scientific Corporation, Inari Medical, Inc., iVascular, S.L.U, Medtronic Plc, Penumbra, Inc., Straub Medical AG (Becton, Dickinson and Company), Teleflex Incorporated, Thrombolex Inc. etc.
Key Questions Answered in This Report:
- How has the global catheter-directed thrombolysis devices market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global catheter-directed thrombolysis devices industry?
- What has been the impact of COVID-19 on the global catheter-directed thrombolysis devices industry?
- What is the breakup of the market based on the delivery mode?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the end user?
- What are the key driving factors and challenges in the global catheter-directed thrombolysis devices industry?
- What is the structure of the global catheter-directed thrombolysis devices industry and who are the key players?
- What is the degree of competition in the global catheter-directed thrombolysis devices industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Catheter-Directed Thrombolysis Devices Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Delivery Mode
- 6.1 Directly Delivery to Blood Clot
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Positioning Medical Device at Clot Site
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Pulmonary Embolism (PE)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Deep Vein Thrombosis (DVT)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Stroke
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Others
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Europe
- 9.2.1 Germany
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 France
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 United Kingdom
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 Italy
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Spain
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Russia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Rest of Europe
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Asia-Pacific
- 9.3.1 China
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 India
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 Japan
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Australia
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 South Korea
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Indonesia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Rest of Asia-Pacific
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Rest of Latin America
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AngioDynamics, Inc
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT
- 14.3.2 Boston Scientific Corporation
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT
- 14.3.3 Inari Medical, Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 iVascular, S.L.U
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Medtronic Plc
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT
- 14.3.6 Penumbra, Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Straub Medical AG (Becton, Dickinson and Company)
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT
- 14.3.8 Teleflex Incorporated
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT
- 14.3.9 Thrombolex Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio